Biggest News Aggregation in the World
📰 Scientific Program News

Page 19 - Scientific Program News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Scientific Program. Real-time updates on events, politics, business and more.

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i
United States San Antonio New Jersey East Hanover Isabella Zinck Thomas Hungerbuehler

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Novartis Pharma AG: Novartis data highlight efficacy of Piqray in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

New data underscore efficacy of Piqray, even in those patients with a short treatment duration on prior CDK4/6i or with ESR1 mutations, biomarkers of endocrine resistance1-5 Recent guideline updates
United States San Antonio New Jersey East Hanover Isabella Zinck Thomas Hungerbuehler

Novartis Pharma AG: New Kisqali data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer

Data from the MONALEESA Phase III program provide further evidence of the unique profile of Kisqali, the CDK4/6 inhibitor with the longest reported median overall survival (OS) in HR+/HER2- metastatic
San Antonio United States New Jersey Comunidad Autonoma De Cataluna East Hanover Isabella Zinck

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science